John G Ullman & Associates Inc. Trims Stock Position in Danaher Co. (NYSE:DHR)

John G Ullman & Associates Inc. cut its holdings in shares of Danaher Co. (NYSE:DHR) by 10.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 914 shares of the conglomerate’s stock after selling 105 shares during the quarter. John G Ullman & Associates Inc.’s holdings in Danaher were worth $228,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in DHR. Cape Investment Advisory Inc. purchased a new position in Danaher during the fourth quarter worth about $25,000. Tsfg LLC increased its stake in Danaher by 733.3% during the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after acquiring an additional 88 shares during the last quarter. BKM Wealth Management LLC acquired a new stake in Danaher during the fourth quarter worth about $27,000. Wetzel Investment Advisors Inc. acquired a new stake in Danaher during the fourth quarter worth about $29,000. Finally, Redmont Wealth Advisors LLC acquired a new stake in Danaher during the first quarter worth about $30,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Alan G. Spoon sold 708 shares of the firm’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total value of $172,454.64. Following the sale, the director now owns 116,202 shares of the company’s stock, valued at approximately $28,304,483.16. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, Director Alan G. Spoon sold 708 shares of the firm’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total value of $172,454.64. Following the sale, the director now owns 116,202 shares of the company’s stock, valued at approximately $28,304,483.16. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Brian W. Ellis sold 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $250.01, for a total value of $1,000,040.00. Following the completion of the sale, the senior vice president now owns 29,830 shares in the company, valued at $7,457,798.30. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 148,783 shares of company stock valued at $37,536,717. Insiders own 11.10% of the company’s stock.

Danaher Stock Up 0.2 %

NYSE DHR traded up $0.57 during mid-day trading on Friday, reaching $246.84. 213,873 shares of the company’s stock traded hands, compared to its average volume of 2,841,726. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $269.11. The company has a fifty day simple moving average of $255.05 and a 200-day simple moving average of $247.31. The company has a current ratio of 1.85, a quick ratio of 1.51 and a debt-to-equity ratio of 0.31. The company has a market cap of $182.83 billion, a price-to-earnings ratio of 41.74, a P/E/G ratio of 3.70 and a beta of 0.83.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The company had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.62 billion. During the same quarter last year, the business posted $2.36 EPS. Danaher’s quarterly revenue was down 2.6% compared to the same quarter last year. As a group, equities research analysts expect that Danaher Co. will post 7.63 EPS for the current year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. The ex-dividend date of this dividend is Friday, June 28th. Danaher’s dividend payout ratio is presently 18.31%.

Analysts Set New Price Targets

DHR has been the subject of several research analyst reports. Robert W. Baird upped their price target on Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 24th. Evercore ISI dropped their price target on Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a research note on Tuesday, July 2nd. Bank of America increased their target price on Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a research note on Wednesday, April 24th. Jefferies Financial Group began coverage on Danaher in a research note on Monday, June 3rd. They issued a “buy” rating and a $295.00 target price for the company. Finally, TD Cowen increased their target price on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Six research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $268.67.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.